Gefitinib ('Iressal', ZD1839) has activity in patients with oestrogen receptor (ER)-negative breast cancer and ER-positive breast cancer that has acquired resistance to tamoxifen: results from a phase II study
BRITISH JOURNAL OF SURGERY（2004）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要